Limits...
Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study.

Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN - Br. J. Cancer (2008)

Bottom Line: Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV status.Overall, 46% of HR HPV cases were positive for the two HR types targeted by the prophylactic vaccines (HPV 16 and HPV 18).The data presented represents the largest type-specific investigation of HPV prevalence in an unselected UK population.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics & Gynaecology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. hibbittssj@cf.ac.uk

ABSTRACT
In this cross-sectional population-based study we determine human papillomavirus (HPV) prevalence in South Wales to provide comprehensive baseline data for future assessment of the impact of prophylactic HPV vaccination and to help inform future screening strategies. Liquid-based cytology samples from women attending routine cervical screening were collected (n=10 000: mean age 38 years, 93% cytology negative, and 64.8% from the 50% least deprived LSOA according to social deprivation score (SDS)). High-Risk (HR) and Low-Risk HPV screening was performed using HPV PCR-EIA with genotyping of HR positives and data correlated with age, SDS and cytology. Overall HPV prevalence was 13.5% (9.3% age standardised) and the most frequent HR types were HPV 16, 31, 18 and 58. In HR HPV-positive cases 42.4% had a single HR type and they were predominant in women with severe cytological abnormalities. Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV status. HPV prevalence increased significantly with degree of dyskaryosis from 7% in cytology negative samples to 80% in samples with severe cytological abnormalities (P-value <0.0001). Overall, 46% of HR HPV cases were positive for the two HR types targeted by the prophylactic vaccines (HPV 16 and HPV 18). The data presented represents the largest type-specific investigation of HPV prevalence in an unselected UK population.

Show MeSH

Related in: MedlinePlus

HPV prevalence distribution by age. The total number of HR HPV, single HR, multiple HR, and LR HPV cases in each age group was calculated as a percentage of the total number of women in the study population (9079) classified as 20–24 years (n=1578), 25–29 years (n=1096), 30–34 years (n=1164), 35–39 years (n=1175), 40–44 years (n=1157), 45–49 years (n=966), 50–54 years (n=739), 55–59 years (n=694) and 60–64 years (n=510).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2600697&req=5

fig3: HPV prevalence distribution by age. The total number of HR HPV, single HR, multiple HR, and LR HPV cases in each age group was calculated as a percentage of the total number of women in the study population (9079) classified as 20–24 years (n=1578), 25–29 years (n=1096), 30–34 years (n=1164), 35–39 years (n=1175), 40–44 years (n=1157), 45–49 years (n=966), 50–54 years (n=739), 55–59 years (n=694) and 60–64 years (n=510).

Mentions: Here, 66% of all HR and 57.6% of LR HPV cases were found in women aged 30 years or less and the prevalence of HR cases decreased progressively with age from 29.4% at 20–24 years to 1.4–2% at ages 50–65 years (Figure 3). In concordance, the majority of all single HR cases (n=262 out of 430) and cases with multiple HR types (n=411 out of 585) were found in women aged 30 years or less. Cases with multiple HR types were more common than single HR cases in all women upto 44 years and this was statistically significant in women aged 30 or less (20–24 years P<0.0001; 25–29 years P=0.0349).


Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study.

Hibbitts S, Jones J, Powell N, Dallimore N, McRea J, Beer H, Tristram A, Fielder H, Fiander AN - Br. J. Cancer (2008)

HPV prevalence distribution by age. The total number of HR HPV, single HR, multiple HR, and LR HPV cases in each age group was calculated as a percentage of the total number of women in the study population (9079) classified as 20–24 years (n=1578), 25–29 years (n=1096), 30–34 years (n=1164), 35–39 years (n=1175), 40–44 years (n=1157), 45–49 years (n=966), 50–54 years (n=739), 55–59 years (n=694) and 60–64 years (n=510).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2600697&req=5

fig3: HPV prevalence distribution by age. The total number of HR HPV, single HR, multiple HR, and LR HPV cases in each age group was calculated as a percentage of the total number of women in the study population (9079) classified as 20–24 years (n=1578), 25–29 years (n=1096), 30–34 years (n=1164), 35–39 years (n=1175), 40–44 years (n=1157), 45–49 years (n=966), 50–54 years (n=739), 55–59 years (n=694) and 60–64 years (n=510).
Mentions: Here, 66% of all HR and 57.6% of LR HPV cases were found in women aged 30 years or less and the prevalence of HR cases decreased progressively with age from 29.4% at 20–24 years to 1.4–2% at ages 50–65 years (Figure 3). In concordance, the majority of all single HR cases (n=262 out of 430) and cases with multiple HR types (n=411 out of 585) were found in women aged 30 years or less. Cases with multiple HR types were more common than single HR cases in all women upto 44 years and this was statistically significant in women aged 30 or less (20–24 years P<0.0001; 25–29 years P=0.0349).

Bottom Line: Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV status.Overall, 46% of HR HPV cases were positive for the two HR types targeted by the prophylactic vaccines (HPV 16 and HPV 18).The data presented represents the largest type-specific investigation of HPV prevalence in an unselected UK population.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics & Gynaecology, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK. hibbittssj@cf.ac.uk

ABSTRACT
In this cross-sectional population-based study we determine human papillomavirus (HPV) prevalence in South Wales to provide comprehensive baseline data for future assessment of the impact of prophylactic HPV vaccination and to help inform future screening strategies. Liquid-based cytology samples from women attending routine cervical screening were collected (n=10 000: mean age 38 years, 93% cytology negative, and 64.8% from the 50% least deprived LSOA according to social deprivation score (SDS)). High-Risk (HR) and Low-Risk HPV screening was performed using HPV PCR-EIA with genotyping of HR positives and data correlated with age, SDS and cytology. Overall HPV prevalence was 13.5% (9.3% age standardised) and the most frequent HR types were HPV 16, 31, 18 and 58. In HR HPV-positive cases 42.4% had a single HR type and they were predominant in women with severe cytological abnormalities. Here, 66% of all HR HPV cases were in women aged 30 years of age or less and SDS had no significant effect on HPV status. HPV prevalence increased significantly with degree of dyskaryosis from 7% in cytology negative samples to 80% in samples with severe cytological abnormalities (P-value <0.0001). Overall, 46% of HR HPV cases were positive for the two HR types targeted by the prophylactic vaccines (HPV 16 and HPV 18). The data presented represents the largest type-specific investigation of HPV prevalence in an unselected UK population.

Show MeSH
Related in: MedlinePlus